SOURCE: Axxess Pharma, Inc.

June 16, 2010 08:00 ET

Axxess Pharma, Inc. Signs Exclusive License Agreement in Canada, Latin America, Middle East and Africa

Anti-fungal, Bacterialcidal, Corticoid Ointments and Creams Now Sold Worldwide Under Axxess Pharma Name in Multi-Billion Dollar Industry

MARKHAM, ON--(Marketwire - June 16, 2010) -  Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they have signed an exclusive license agreement to manufacture and distribute non-prescription drugs in Canada, Latin America, Middle East and Africa. Axxess Pharma will also be the first company to introduce a unique herbal, non-alcohol based antiseptic hand wash and disinfectant to the Canadian market.

The Company is now marketing the medications under the Axxess Pharma name. These products include antifungal, Bacterialcidal, Corticoid ointment and creams.

Orders are currently being processed worldwide with a guarantee of quick shipment. The Company anticipates revenues will increase year over year by a minimum of 300 percent. Current annual global sales within this market sector are estimated between $400 million to $500 million.

"This exclusive license agreement will substantially increase our revenue base and allow us to increase market share worldwide under our brand name 'Axxess Pharma.' We are especially excited to be the first company to introduce a unique herbal, non-alcoholic antiseptic hand wash in Canada," stated Gerald Sequeira, President/CEO. Consumers are becoming increasingly aware of the dangers of alcohol based sanitizers. Most sanitizers in the market today contain 60 percent to 90 percent alcohol (commonly ethyl or isopropyl alcohol). Hospitals and consumers around the world are becoming increasingly aware this alcohol is poisoning adults and most importantly children and the elderly. Even the smallest use of sanitizers which contain large concentrations of alcohol can lead to several serious dangers including dizziness, headaches, blurred speech and brain damage (in extreme cases). This new realization is now creating a shift in demand to products such as our non-alcohol based hand sanitizers. We are in prime position to capture significant market share and revenue in this area," stated Mr. Sequeira.

For more information, please contact Investor Relations at (973) 351-3868 or visit www.axxesspharma.com.

About Axxess Pharma, Inc.:

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Safe Harbor

Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.

Contact Information

  • Contact:
    Taylor Capitol, Inc.
    Investor Relations
    Stephen Taylor
    973-351-3868
    Email Contact